CTOs on the Move

Umoja Biopharma

www.umoja-biopharma.com

 
Umoja is developing a new approach to cancer therapy that retools a patient`s immune system in vivo, enhancing the body`s natural capacity to fight cancer. We envision a world where all patients with cancer have access to the most advanced immunotherapies and are free from the burdens of traditional cancer therapies.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Umoja Biopharma raised $53M on 11/18/2020
Umoja Biopharma raised $210M on 06/15/2021

Similar Companies

Martin Bionics

A paradigm shift in prosthetic comfort and quality of life. The Socket-less Socket™ fits like a sneaker providing comfort and control for all amputation levels.

MAP Pharmaceuticals

MAP Pharmaceuticals is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Children's Health Council

We understand that mental health needs often increase in times of uncertainty. Concerned? Please reach out. CHC is currently accepting new referrals.

Dompé

Dompé: un impegno costante nella ricerca scientifica per lo sviluppo di farmaci innovativi per migliorare lo stato di salute dell’uomo

Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera`s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful, including lupus nephritis, a severe renal manifestation of systemic lupus erythematosus.